Affordable Access

Androgen receptor as a therapeutic target for androgen independent prostate cancer.

Authors
Type
Published Article
Journal
American journal of therapeutics
Publication Date
Volume
13
Issue
2
Pages
166–170
Identifiers
PMID: 16645434
Source
Medline

Abstract

Prostate cancer is the leading cause of nonskin malignancy and the second leading cause of cancer death in men. Androgen deprivation therapy is the first-line of systemic therapy against advanced prostate cancer. All advanced prostate cancers eventually grow despite castrate levels of testosterone. We review the evidence that androgen independent prostate cancer continues to require androgen receptor activity for growth, the mechanisms of androgen receptor activation in the castrate setting, and possible points of intervention for novel therapies targeting the androgen receptor and prostate cancer.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments